Sage Therapeutics Inc

Sage Therapeutics Inc Stock Forecast & Price Prediction

Live Sage Therapeutics Inc Stock (SAGE) Price
$6.05

15

Ratings

  • Buy 14
  • Hold 1
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$6.05

P/E Ratio

-0.67

Volume Traded Today

$1.1M

Dividend

Dividends not available for SAGE

52 Week High/low

28.26/5.84

Sage Therapeutics Inc Market Cap

$371.9M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $SAGE ๐Ÿ›‘

Before you buy SAGE you'll want to see this list of ten stocks that have huge potential. Want to see if SAGE made the cut? Enter your email below

SAGE Summary

From what 15 stock analysts predict, the share price for Sage Therapeutics Inc (SAGE) might increase by 68.26% in the next year. This is based on a 12-month average estimation for SAGE. Price targets go from $4 to $26. The majority of stock analysts believe SAGE is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

SAGE Analyst Ratings

SAGE is a stock in Healthcare which has been forecasted to be worth $10.18 as an average. On the higher end, the forecast price is $26 USD by Brian Abrahams from RBC Capital and on the lower end SAGE is forecasted to be $4 by Brian Abrahams from RBC Capital.

SAGE stock forecast by analyst

These are the latest 20 analyst ratings of SAGE.

Analyst/Firm

Rating

Price Target

Change

Date

Yasmeen Rahimi
Piper Sandler

Overweight

$26

Reiterates

Oct 30, 2024
Douglas Tsao
HC Wainwright & Co.

Neutral

$14

Maintains

Oct 30, 2024
Joon Lee
Truist Securities

Hold

$8

Maintains

Oct 30, 2024
Jay Olson
Oppenheimer

Perform

$8

Maintains

Oct 30, 2024
George Farmer
Scotiabank

Sector Outperform

$14

Maintains

Oct 30, 2024
Ami Fadia
Needham

Hold


Reiterates

Oct 30, 2024
Ami Fadia
Needham

Hold


Reiterates

Oct 17, 2024
Danielle Brill
Raymond James

Market Perform


Reinstates

Oct 10, 2024
Tazeen Ahmad
B of A Securities

Underperform

$6

Maintains

Oct 9, 2024
Joel Beatty
Baird

Neutral

$9

Maintains

Oct 9, 2024
Laura Chico
Wedbush

Neutral

$8

Maintains

Oct 9, 2024
Douglas Tsao
HC Wainwright & Co.

Neutral

$25

Reiterates

Oct 9, 2024
Ami Fadia
Needham

Hold


Reiterates

Oct 8, 2024
Brian Abrahams
RBC Capital

Underperform

$4

Downgrade

Oct 4, 2024
Joon Lee
Truist Securities

Hold

$13

Maintains

Aug 14, 2024
Anupam Rama
JP Morgan

Neutral

$10

Maintains

Aug 6, 2024
Douglas Tsao
HC Wainwright & Co.

Neutral

$25

Reiterates

Aug 2, 2024

Piper Sandler

Overweight


Maintains

Aug 1, 2024
Ami Fadia
Needham

Hold


Reiterates

Aug 1, 2024
Ritu Baral
TD Cowen

Hold

$10

Downgrade

Jul 30, 2024

SAGE Company Information

What They Do: Develops brain health medicines for various conditions.

Business Model: Sage Therapeutics focuses on developing and commercializing innovative treatments for neurological and psychiatric disorders. The company generates revenue through the sale of its FDA-approved products, such as ZULRESSO for postpartum depression, and through strategic collaborations and licensing agreements with other pharmaceutical companies to advance its drug pipeline.

Other Information: Sage Therapeutics has a diverse product pipeline that includes several candidates in various stages of clinical trials targeting conditions like essential tremors, epilepsy, Parkinson's disease, and multiple psychiatric disorders. The company's strategic partnerships with organizations like Shionogi & Co., Ltd. and Biogen MA Inc. enhance its research capabilities and market reach, particularly in international markets.
SAGE
Sage Therapeutics Inc (SAGE)

When did it IPO

2014

Staff Count

487

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. Barry E. Greene

Market Cap

$371.9M

Sage Therapeutics Inc (SAGE) Financial Data

In 2023, SAGE generated $86.5M in revenue, which was a increase of 1,024.84% from the previous year. This can be seen as a signal that SAGE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$1.11B

Revenue From 2021

$6.3M

-99.43 %
From Previous Year

Revenue From 2022

$7.7M

21.85 %
From Previous Year

Revenue From 2023

$86.5M

1,024.84 %
From Previous Year
  • Revenue TTM $106.4M
  • Operating Margin TTM -822.2%
  • Gross profit TTM $84.3M
  • Return on assets TTM -61.4%
  • Return on equity TTM -67.7%
  • Profit Margin 97.5%
  • Book Value Per Share 10.31%
  • Market capitalisation $371.9M
  • Revenue for 2021 $6.3M
  • Revenue for 2022 $7.7M
  • Revenue for 2023 $86.5M
  • EPS this year (TTM) $-5.57

Sage Therapeutics Inc (SAGE) Latest News

News Image

Wed, 30 Oct 2024

Sentiment - NEGATIVE

Source - Zacks Investment Research

Summary - Sage Therapeutics reported Q3 2024 earnings that missed estimates, resulting in a decline in stock price during after-hours trading.

Why It Matters - Earnings misses can signal operational issues or reduced growth potential, leading to decreased investor confidence and stock price declines. This impacts overall market sentiment toward the company.

News Image

Tue, 29 Oct 2024

Sentiment - NEUTRAL

Source - Seeking Alpha

Summary - Sage Therapeutics will host its Q3 2024 earnings conference call on October 29, 2024, at 4:30 PM ET, featuring key executives including the CEO and CFO.

Why It Matters - Sage Therapeutics' earnings call signals potential updates on financial performance and pipeline progress, influencing stock valuation and investor sentiment.

News Image

Mon, 28 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - A class action lawsuit has been filed against Sage Therapeutics, Inc. (NASDAQ: SAGE) and its officers, as announced by law firm Bronstein, Gewirtz & Grossman, LLC.

Why It Matters - A class action lawsuit against Sage Therapeutics could lead to financial liabilities, regulatory scrutiny, and impact stock performance, prompting investors to reassess their positions.

News Image

Mon, 28 Oct 2024

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - A class action lawsuit has been filed against Sage Therapeutics (NASDAQ: SAGE) for securities violations. Investors who bought shares from April 12, 2021, to July 23, 2024, should contact the Schall Law Firm before October 28, 2024.

Why It Matters - The class action lawsuit against Sage Therapeutics may signal potential legal and financial risks, impacting stock performance and investor sentiment regarding the company's future.

News Image

Sun, 27 Oct 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - A class action lawsuit has been filed against Sage Therapeutics (NASDAQ:SAGE) for alleged violations of federal securities laws during the period from April 12, 2021, to July 23, 2024.

Why It Matters - A class action lawsuit against Sage Therapeutics may lead to financial liabilities and reputational damage, impacting stock performance and investor sentiment.

News Image

Mon, 28 Oct 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - Sage Therapeutics, Inc. (NASDAQ:SAGE) investors who suffered losses may explore potential recovery under federal securities laws. More info is available via the provided link or by contacting legal counsel.

Why It Matters - The news indicates potential legal action against Sage Therapeutics, which may affect the company's stock price and investor sentiment, highlighting risks in ongoing investments.

...

SAGE Frequently asked questions

The highest forecasted price for SAGE is $26 from Brian Abrahams at RBC Capital.

The lowest forecasted price for SAGE is $4 from Brian Abrahams from RBC Capital

The SAGE analyst ratings consensus are 14 buy ratings, 1 hold ratings, and 0 sell ratings.